ClinicalTrials.gg
CompletedNCT03998683G-PLUSUpdated Jan 3, 2022

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

A Phase 3 interventional study of Guselkumab 100 mg and Placebo in Psoriasis, sponsored by Janssen-Cilag Ltd.. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-03.

Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
17th of 29
117 · median 120
Started
2019
with 1 other
Phase 3
12 of 29
none open now
Registered
15th of 29
by date
Lead sponsor
2 of 29
Janssen-Cilag Ltd.

Among the 29 studies testing guselkumab in Psoriasis, this one is the 17th largest by enrollment, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 15th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab for the treatment of palmoplantar psoriasis.

Read the detailed description

Chronic plaque psoriasis is the most common form of psoriatic skin disease; however, there is growing evidence that other variants including scalp, nail, inverse, and palmoplantar psoriasis are prevalent, undertreated, and are correlated with an increased risk of psoriatic arthritis that may result in significant morbidity with functional impairment and greater impairment in quality of life. Therefore, the main aim of the study is to provide robust efficacy and safety data on guselkumab treatment for palmoplantar non-pustular psoriasis. The study comprises of a Screening Phase (4 Weeks [Week -4 to 0]), a Treatment Phase (up to Week 48) and a post-treatment follow-up phase (up to Week 56). Key efficacy assessments include physician assessments and patient-reported outcomes questionnaires. Safety evaluations will include 12-lead electrocardiogram at baseline, pregnancy testing and monitoring of vital signs at all visits and recording of adverse events throughout the study. Also, participants will be evaluated for signs and symptoms of active tuberculosis at all visits including follow-up visit. Biomarker assessments will include the evaluation of relevant markers in serum for all participants. The study will have an overall duration of 56 weeks.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Should have all the following: A confirmed diagnosis of moderate-to-severe palmoplantar-non-pustular psoriasis with palm and/or sole involvement and at least one plaque at a body site other than the palms and soles for at least 6 months, to confirm a diagnosis of chronic psoriasis; psoriatic area and severity index (PASI) score greater than or equal to (>=) 3 and less than (\<) 10 at screening and at baseline; Palmoplantar Investigator Global Assessment (ppIGA) score >=3 at screening and at baseline
  • Should be eligible to receive biological treatments; only participants who are naive to biological treatments can be included
  • A woman of must have a negative urine pregnancy test at screening and at Week 0
  • Agree not to receive a live virus or live bacterial vaccination during the study, or within 12 weeks after the last administration of study intervention
  • Agree to avoid prolonged sun exposure and agree not to use tanning booths or other ultraviolet (UV) light sources from the first administration of study intervention through 12 weeks after the final dose of study intervention (Week 56)

Exclusion criteria

Exclusion Criteria:

  • Currently has palmoplantar pustulosis, pustular psoriasis, or any other forms other than plaque-type psoriasis (e.g, erythrodermic, guttate), or hyperkeratotic eczema
  • Has current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Has received prior systemic treatment with biological agents or Janus Kinase (JAK) inhibitors
  • Has had prior exposure, known and reported intolerance to guselkumab or , or ineligible to treatment with biological agents
  • Is infected with (HIV, positive serology for HIV antibody)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Guselkumab Group

    Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.

    Drug: Guselkumab 100 mg · Drug: Placebo

  • Placebo comparator
    Placebo Group

    Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.

    Drug: Guselkumab 100 mg · Drug: Placebo

Interventions

  • Guselkumab 100 mg will be administered as SC injection.

    Also known as: CNTO1959

  • DrugPlacebo

    Placebo will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve Palmoplantar Pustulosis Psoriasis Area and Severity Index 75 (ppPASI75) Response at Week 16

    Percentage of participants who achieve ppPASI75 response, defined as improvement greater than or equal to (\>=) 75 percent (%) in the ppPASI score at Week 16 will be reported. The ppPASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of disease of the palms and/or soles.

    Time frame: Week 16

Secondary outcomes

  1. Change from Baseline in Body Surface Area (BSA) Score at Weeks 16, 24 and 48

    Change from baseline in BSA score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups by measuring the arithmetic mean of the affected skin surface.

    Time frame: Baseline and Weeks 16, 24 and 48

  2. Change from Baseline in absolute PASI Score at Weeks 16, 24 and 48

    Change from baseline in absolute PASI score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups.

    Time frame: Baseline, Weeks 16, 24 and 48

  3. Percentage of Participants Achieving PASI 75 Score at Weeks 16, 24 and 48

    Percentage of participants achieving PASI 75 score (participants who achieve \>=75% improvement in PASI score) at Weeks 16, 24 and 48 will be reported in guselkumab versus the placebo group. PASI is a common clinical tool used to measure the severity and extent of psoriasis. The PASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of disease of the palms and/or soles.

    Time frame: Weeks 16, 24 and 48

  4. Percentage of Participants Achieving PASI 90 Score at Weeks 16, 24 and 48

    Percentage of participants achieving PASI 90 score (participants who achieve \>=90 % improvement in PASI score) at Weeks 16, 24 and 48 will be reported in guselkumab versus the placebo group. PASI is a common clinical tool used to measure the severity and extent of psoriasis. The PASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of disease of the palms and/or soles.

    Time frame: Weeks 16, 24 and 48

  5. Percentage of Participants Achieving PASI 100 at Weeks 16, 24 and 48

    Percenatge of participants who achieving PASI 100 score (participants who achieve \>=100 % improvement in PASI score) at Weeks 16, 24 and 48 will be reported in guselkumab versus the placebo group. PASI is a common clinical tool used to measure the severity and extent of psoriasis. The PASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of disease of the palms and/or soles.

    Time frame: Weeks 16, 24 and 48

  6. Change from Baseline in Palmoplantar Quality-of-Life Instrument (ppQLI) Score at Weeks 16, 24 and 48

    Change from baseline in ppQLI score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. ppQLI assesses relevant dimensions affected by palmoplantar psoriasis (pain/discomfort, functionality, and social/activity limitations) to assess quality of life.

    Time frame: Baseline and Weeks 16, 24 and 48

  7. Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Weeks 16, 24 and 48

    Change from baseline in DLQI score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. DLQI a 10-item questionnaire that can be used to assess overall quality-of-life.

    Time frame: Baseline and Weeks 16, 24 and 48

  8. Change from Baseline in European Quality of Life, 5-Dimension, 5-Level (EQ-5D-5L) Score at Weeks 16, 24 and 48

    Change from baseline in EQ-5D- 5L score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. EQ-5D-5L is a standardized instrument to measure health-related quality of life.

    Time frame: Baseline and Weeks 16, 24 and 48

  9. Change from Baseline in Palmoplantar Investigator Global Assessment (ppIGA) Score at Weeks 16, 24 and 48

    Change from baseline in ppIGA score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups to assess psoriasis overall lesions.

    Time frame: Baseline and Weeks 16, 24 and 48

  10. Change from Baseline in Fingernail-Physician Global Assessment (f-PGA) Score at Weeks 16, 24 and 48

    Change from baseline in f-PGA score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups to assess fingernails separately for nail bed and nail matrix for signs of disease.

    Time frame: Baseline and Weeks 16, 24 and 48

  11. Percentage of Participants who Achieve ppPASI75 response at Weeks 24 and 48

    Percentage of participants who achieve ppPASI75 response, defined as improvement \>=75% in the ppPASI score at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. The ppPASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of disease of the palms and/or soles.

    Time frame: Weeks 24 and 48

  12. Percentage of Participants who Achieve ppPASI90 response at Weeks 24 and 48

    Percentage of participants who achieve ppPASI90 response (participants who achieve \>=90 % improvement in the ppPASI score) at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. The ppPASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of the affection of the palms and/or soles.

    Time frame: Weeks 24 and 48

  13. Percentage of Participants who Achieve ppPASI100 response at Weeks 24 and 48

    Percentage of participants who achieve ppPASI100 response (participants who achieve \>=100 % improvement in the ppPASI score) at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. The ppPASI is an assessment tool based on the PASI that assesses erythema, pustules, desquamation and the extent of the affection of the palms and/or soles.

    Time frame: Weeks 24 and 48

  14. Change from Baseline in Work Productivity and Activity Impairment: Psoriasis (WPAI: PSO) Score at Weeks 16, 24 and 48

    Change from baseline in WPAI: PSO score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. WPAI-PSO is a questionnaire which includes 6 questions to measure work productivity and activity impairment related to skin psoriasis.

    Time frame: Baseline and Weeks 16, 24 and 48

  15. Change from Baseline in Numerical Rating Scale: Pain (NRS:P) Score at Weeks 16, 24 and 48

    Change from baseline in NRS:P score at Week 16 will be reported in the guselkumab versus placebo group and at Weeks 24 and 48 will be reported separately for guselkumab and placebo-crossover groups. NRS:P is a self-administered scale that assess pain intensity in participants.

    Time frame: Baseline and Weeks 16, 24 and 48

  16. Number of Participants with Adverse Event (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to 56 weeks

07

Study locations

26 sites
  • CHU Bordeaux - Hopital St Andre
    Bordeaux, 33000, France
  • Hôpital Edouard Herriot
    Lyon Cedex 03, 69437, France
  • CHU de Nice Hopital de l Archet
    Nice, 06200, France
  • Hopital Charles Nicolle
    Rouen, 76031, France
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • University Hospital Dresden
    Dresden, 01307, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • MensingDerma research GmbH
    Hamburg, 22391, Germany
  • Universitätsklinikum Schleswig Holstein Campus Lübeck
    Lubeck, 23538, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany
  • Centrovital
    Witten, 58453, Germany
  • AOU di Cagliari
    Cagliari, 09124, Italy
  • P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
    Catania, 95123, Italy
  • Ospedale Santa Chiara AO Universitaria Pisana
    Pisa, 56126, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Hosp. Univ. Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hosp. Univ. Infanta Leonor
    Madrid, 28031, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
  • Hosp. de Manises
    Valencia, 46940, Spain
  • Russell's Hall Hospital
    Dudley, DY1 2HQ, United Kingdom
  • Chapel Allerton Hospital
    Leeds, LS7 4SA, United Kingdom
  • Barts Health NHS Trust
    London, E11 1NR, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Salford Royal NHS Foundation Trust
    Salford, M6 8HD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Mar 2021, 17 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2019
First posted
Jun 26, 2019
StartActual
Sep 3, 2019
Primary completionActual
Mar 2, 2021
CompletionActual
Nov 30, 2021
Last update
Jan 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03998683
Lead sponsor
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
Jun 26, 2019
Start date
Sep 3, 2019
Primary completion
Mar 2, 2021
Completion
Nov 30, 2021
Last update
Jan 3, 2022

Study contacts

Janssen-Cilag Ltd. Clinical Trial
study director · Janssen-Cilag Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion